Bioimpact Capital LLC
BioImpact Capital LLC, also known as MPM BioImpact LLC, is a venture capital investment firm headquartered in Boston, Massachusetts. It specializes in biotechnology and life sciences, supporting the development of innovative therapies by investing in early- and late-stage biotech companies. The firm, previously known as MPM Oncology Impact Management LP, operates out of its Boston office and employs approximately 50 professionals, as reported in 2024. BioImpact Capital serves institutional clients, primarily through pooled investment vehicles, and has been active in the field under the MPM brand for multiple decades.
Investment Strategy
BioImpact Capital focuses on venture capital investing in biotechnology and life sciences, targeting companies with breakthrough therapies that have the potential to transform patient outcomes. The firm seeks investments across various stages of development, from early innovation to later-stage growth, aiming to leverage deep sector expertise and scientific rigor to identify and support high-impact enterprises. The strategy emphasizes partnerships with pioneering companies and teams in the biotech sector, and the creation of meaningful value through hands-on investment and company-building.
Top Holdings
Equity Positions (44)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
C CGEM | Cullinan Therapeutics, Inc. | 9.98% | $57.6M | 7,648,268 | $41.67 | $7.53 | -$305.9K |
M MDGL | Madrigal Pharmaceuticals Inc | 5.27% | $30.4M | 100,415 | $331.23 | $302.64 | -$2.9M |
Z ZLAB | Zai Lab Ltd | 4.51% | $26.1M | 745,060 | $26.59 | $34.97 | -$4.1M |
G GH | Guardant Health Inc | 3.99% | $23.0M | 442,656 | $28.26 | $52.04 | +$4.2M |
S SPRY | ARS Pharmaceuticals Inc | 3.94% | $22.7M | 1,303,399 | $12.58 | $17.45 | +$6.2M |